CAMP4 Therapeutics Corporation (CAMP) Spending and interest coverage
- R&D / revenue · 12 months: Value 917.69%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 131.36%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 917.69% | Research and development expense / revenue. Period ending 2026-06-30. $38.69M ÷ $4.22M × 100 ≈ 917.69% |
| Stock-based compensation / revenue · 12 months | 131.36% | Share-based compensation / revenue. Period ending 2026-06-30. $5.54M ÷ $4.22M × 100 ≈ 131.36% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 38.69M USD | Research and Development Expense |
| Revenue | 4.22M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 5.54M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -52.88M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $38.69M | $4.22M | $5.54M | $-52.88M | (m) | 917.69% | 131.36% | (m) | (m) |
| 2026-03-31 | $38.22M | $3.93M | $4.61M | $-52.53M | (m) | 971.43% | 117.16% | (m) | (m) |
| 2025-12-31 | $38.20M | $3.50M | $4.00M | $-52.55M | (m) | 1092.11% | 114.29% | (m) | (m) |
| 2025-09-30 | $39.84M | $3.80M | $3.64M | $-53.81M | (m) | 1047.90% | 95.84% | (m) | (m) |
| 2025-06-30 | $40.18M | $3.01M | $4.25M | $-53.68M | (m) | 1336.12% | 141.44% | (m) | (m) |
| 2025-03-31 | $39.22M | $1.51M | $4.04M | $-53.31M | (m) | 2597.55% | 267.35% | (m) | (m) |
| 2024-12-31 | $38.82M | $652.00K | $4.03M | $-53.09M | (m) | 5953.53% | 618.40% | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $40.62M | $350.00K | $2.91M | $-51.88M | (m) | 11604.57% | 830.57% | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |